212 related articles for article (PubMed ID: 27055865)
1. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.
Kong G; Chang YI; Damnernsawad A; You X; Du J; Ranheim EA; Lee W; Ryu MJ; Zhou Y; Xing Y; Chang Q; Burd CE; Zhang J
Leukemia; 2016 Jul; 30(7):1542-51. PubMed ID: 27055865
[TBL] [Abstract][Full Text] [Related]
2. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
[TBL] [Abstract][Full Text] [Related]
3. Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.
Staffas A; Karlsson C; Persson M; Palmqvist L; Bergo MO
Leukemia; 2015 May; 29(5):1032-40. PubMed ID: 25371176
[TBL] [Abstract][Full Text] [Related]
4. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
5. Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.
Wen Z; Yun G; Hebert A; Kong G; Ranheim EA; Finn R; Rajagoplan A; Li S; Zhou Y; Yu M; Damnernsawad A; Roose JP; Coon JJ; Wen R; Wang D; Zhang J
Blood; 2021 Jun; 137(23):3259-3271. PubMed ID: 33512434
[TBL] [Abstract][Full Text] [Related]
6. Downregulating Notch counteracts Kras
Kong G; You X; Wen Z; Chang YI; Qian S; Ranheim EA; Letson C; Zhang X; Zhou Y; Liu Y; Rajagopalan A; Zhang J; Stieglitz E; Loh M; Hofmann I; Yang D; Zhong X; Padron E; Zhou L; Pear WS; Zhang J
Leukemia; 2019 Mar; 33(3):671-685. PubMed ID: 30206308
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; PasseguƩ E; Shannon K; Braun BS
PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
Zhang J; Wang J; Liu Y; Sidik H; Young KH; Lodish HF; Fleming MD
Blood; 2009 Feb; 113(6):1304-14. PubMed ID: 19066392
[TBL] [Abstract][Full Text] [Related]
9. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; CaƱamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
10. Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals.
Du J; Liu Y; Meline B; Kong G; Tan LX; Lo JC; Wang J; Ranheim E; Zhang L; Chang YI; Ryu MJ; Zhang JF; Zhang J
Leukemia; 2013 Mar; 27(3):754-7. PubMed ID: 22976127
[No Abstract] [Full Text] [Related]
11. NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.
Aydin E; Hallner A; Grauers Wiktorin H; Staffas A; Hellstrand K; Martner A
Oncogene; 2019 Feb; 38(9):1534-1543. PubMed ID: 30323311
[TBL] [Abstract][Full Text] [Related]
12. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
[TBL] [Abstract][Full Text] [Related]
13. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.
Melo-Cardenas J; Xu Y; Wei J; Tan C; Kong S; Gao B; Montauti E; Kirsammer G; Licht JD; Yu J; Ji P; Crispino JD; Fang D
Blood; 2018 Jul; 132(4):423-434. PubMed ID: 29844011
[No Abstract] [Full Text] [Related]
14. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
[TBL] [Abstract][Full Text] [Related]
15. Kras is Required for Adult Hematopoiesis.
Damnernsawad A; Kong G; Wen Z; Liu Y; Rajagopalan A; You X; Wang J; Zhou Y; Ranheim EA; Luo HR; Chang Q; Zhang J
Stem Cells; 2016 Jul; 34(7):1859-71. PubMed ID: 26972179
[TBL] [Abstract][Full Text] [Related]
16. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
Weyandt J
Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
[TBL] [Abstract][Full Text] [Related]
17. Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.
Wang J; Liu Y; Tan LX; Lo JC; Du J; Ryu MJ; Ranheim EA; Zhang J
Cell Cycle; 2011 Sep; 10(17):2836-9. PubMed ID: 21857161
[TBL] [Abstract][Full Text] [Related]
18. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
19. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
Braun BS; Tuveson DA; Kong N; Le DT; Kogan SC; Rozmus J; Le Beau MM; Jacks TE; Shannon KM
Proc Natl Acad Sci U S A; 2004 Jan; 101(2):597-602. PubMed ID: 14699048
[TBL] [Abstract][Full Text] [Related]
20. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]